Enteropathogenic Escherichia coli (EPEC) is a significant bacterial pathogen known for causing severe gastrointestinal diseases, particularly in children. EPEC employs various strategies to ...

A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an independent data monitoring committee (IDMC) determined that Sanofi and Johnson & Johnson’s ...

Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical studyIndependent interim analysis of the E.mbrace phase 3 study finds that ...

The company said it will stop the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over ...

French pharma major Sanofi’s saw its shares edge up 1% by early afternoon, despite announcing a disappointment for a vaccine ...

Due to the discontinuation, Sanofi said that it has recorded an impairment charge before tax of $250 million in the Q4 2024 ...

A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vaccines unit to pick up an E. coli candidate, ...

Sanofi ( ($SNY) ) has provided an announcement. On February 13, 2025, Sanofi announced the discontinuation of the E.mbrace phase 3 study for its ...